Anticancer molecules targeting fibroblast growth factor receptors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases crucial for cell signaling.
• FGFR signaling pathways, including MAPK and PI3K/Akt, regulate tumor cell proliferation, angiogenesis, migration, and survival.
• Dysregulated FGFR signaling is implicated in various cancers, making FGFRs attractive therapeutic targets.

Purpose of the Study:

• To review recent advances in the structure-activity relationships (SAR) of FGFR inhibitors.
• To discuss drug design strategies for targeting deregulated FGFRs using antibodies and small molecule inhibitors.

Main Methods:

• Review of preclinical studies involving knockdown and pharmaceutical inhibition of FGFRs.
• Analysis of structure-activity relationships (SAR) for various FGFR inhibitors.
• Evaluation of drug design strategies for FGFR-targeting antibodies and small molecules.

Main Results:

• FGFRs are validated targets for cancer therapy, with multiple inhibitors developed.
• Significant progress has been made in understanding the SAR of FGFR inhibitors.
• Diverse strategies are employed for designing FGFR-targeting drugs.

Conclusions:

• FGFR inhibitors represent a promising therapeutic avenue for cancer treatment.
• Continued research into SAR and drug design will refine FGFR-targeted therapies.
• Antibodies and small molecules offer distinct approaches for inhibiting deregulated FGFRs.